Adam Bonislawski

The company is working with early-access users and recently published a preprint detailing use of the system to map cell surface proteins in T cells.

Significant recent improvements in depth of coverage and throughput have substantial implications for both researchers and companies in the space.

While the method is still in its early stages, it points the way toward a very high-throughput workflow for top-down single-cell proteomics.

While computing power remains a challenge, AI-based methods could complement existing tools like mass spectrometry and yeast two-hybrid systems.

The new instruments could substantially boost proteomic analyses and address challenges in applications including single-cell and plasma proteomics.

The work indicates the potential of mass spectrometry for proteogenomic applications that have been dominated by affinity-based platforms.

In work supported by the Michael J. Fox Foundation, the researchers identified protein markers for the condition in extracellular vesicles collected from urine.

The firm said the acquisition let it move into the "fast growing" MRD space and round out its offerings in cancer screening, pathology, and sequencing.

During its Q1 earnings call, the company said that hospitals that had paused lab system purchases during COVID-19 were reentering the market.

The company expects its NULISA system will compete with firms like Olink and SomaLogic in the high-plex, high-throughput proteomics space.